A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast

Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.

Authors

Institutions

Publication Details

Journal
Discover Oncology
Published
2025-07-16
DOI
https://doi.org/10.1007/s12672-025-03107-9
Primary Topic
Breast Lesions and Carcinomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast

Tianhai Du, Lingping Xie, Chao Wang
Discover Oncology
Breast Lesions and Carcinomas
article

A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast

Tianhai Du, Lingping Xie, Chao Wang
article en

Abstract

Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.

Discover OncologyVol. 16(1)
Chengdu Medical College (CN), Sichuan University (CN), West China Hospital of Sichuan University (CN)
Zero hunger
Openalex Percentile: Top 74%
Breast Lesions and Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.